- |||||||||| Lartruvo (olaratumab) / Eli Lilly
Review, Journal: Olaratumab for Advanced Soft Tissue Sarcoma. (Pubmed Central) - Jul 1, 2017 P3 Of importance, this clinically meaningful increase in overall survival did not come at the expense of a significantly greater number of toxicities. A phase III confirmatory trial (ClinicalTrials.gov Identifier NCT02451943) will be completed in 2020.
- |||||||||| Enrollment open: A Study of Lymphoseek (clinicaltrials.gov) - Jun 29, 2017
P2, N=27, Recruiting, Trial primary completion date: Jan 2018 --> Aug 2018 Active, not recruiting --> Recruiting
- |||||||||| CBT-1 (tetrandrine) / CBA Pharma
Trial initiation date, Trial primary completion date, Combination therapy, Metastases: CBT-1 (clinicaltrials.gov) - Jun 29, 2017 P1, N=46, Not yet recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Nov 2017 Initiation date: Jan 2017 --> Sep 2017 | Trial primary completion date: Dec 2019 --> Sep 2020
- |||||||||| Halaven (eribulin mesylate) / Eisai
Trial primary completion date: HAL03T: A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - Jun 27, 2017 P=N/A, N=160, Recruiting, A detailed clinicopathologic correlation and supplementing the EWSR1 FISH assay with complementary methodology is mandatory for correct diagnosis. Trial primary completion date: Jun 2017 --> Nov 2018
- |||||||||| Trial primary completion date: Proton or Photon RT for Retroperitoneal Sarcomas (clinicaltrials.gov) - Jun 26, 2017
P1/2, N=80, Recruiting, Not yet recruiting --> Active, not recruiting | N=16 --> 20 Trial primary completion date: Jun 2017 --> Dec 2019
- |||||||||| robatumumab (SCH 717454) / Merck (MSD)
Journal: A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. (Pubmed Central) - Jun 25, 2017 P2 This activity was observed at MK-8242 drug exposures that appear to exceed those observed in human phase 1 trials. These findings show that although the IGF-1R remains an attractive treatment target, additional research is needed to identify responders and/or means to achieve durable remissions in order to successfully exploit IGF-1R signal blockade in Ewing sarcoma (clinicaltrials.gov: NCT00617890).
- |||||||||| Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients With Metastatic Sarcoma Stable on Chemotherapy (clinicaltrials.gov) - Jun 23, 2017
P2, N=9, Active, not recruiting, Primary intrapelvic hemangiosarcoma is rare in dogs. Recruiting --> Active, not recruiting | N=36 --> 9 | Trial primary completion date: Dec 2017 --> Aug 2017
- |||||||||| Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Takeda, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Trial primary completion date, Metastases: Cabozantinib for Adults With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 21, 2017 P2, N=50, Recruiting, Trial primary completion date: Jun 2017 --> Sep 2021 Trial primary completion date: Jun 2017 --> Jan 2018
- |||||||||| CBT-1 (tetrandrine) / CBA Pharma
Enrollment change, Trial withdrawal, Combination therapy, Metastases: CBT-1 (clinicaltrials.gov) - Jun 20, 2017 P1, N=0, Withdrawn, Trial primary completion date: Dec 2017 --> Dec 2018 N=46 --> 0 | Suspended --> Withdrawn
- |||||||||| RRx-001 / EpicentRx
Biomarker, Journal: Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors. (Pubmed Central) - Jun 19, 2017 The T150 min of CHP-100 tumors recovered to baseline by 24 h post-drug, suggesting a robust anti-oxidant response to the RRx-001 challenge that was presaged by a marked increase in perfusion at 1 h post-drug measured by DCE-MRI. MRI enhanced with Gd-LC7-SH provides a mechanistically rational biomarker of RRx-001 pharmacodynamics.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Monotherapy, Metastases: Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (clinicaltrials.gov) - Jun 19, 2017 P3, N=216, Recruiting, MRI enhanced with Gd-LC7-SH provides a mechanistically rational biomarker of RRx-001 pharmacodynamics. Not yet recruiting --> Recruiting
- |||||||||| Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Enrollment open: ADVL1622: Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (clinicaltrials.gov) - Jun 19, 2017 P2, N=110, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Avastin (bevacizumab) / Roche
Enrollment closed, Enrollment change, Trial primary completion date, Monotherapy, IO biomarker, Metastases: Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma (clinicaltrials.gov) - Jun 16, 2017 P2, N=16, Active, not recruiting, She developed continuing liver failure, from which she died despite good cardiac function. Recruiting --> Active, not recruiting | N=26 --> 16 | Trial primary completion date: Oct 2017 --> May 2015
- |||||||||| Fyarro (nanoparticle albumin-bound rapamycin) / Aadi Biosci, Opdivo (nivolumab) / BMS
New P1 trial, PD(L)-1 Biomarker, IO biomarker, Metastases: Nivolumab (Opdivo (clinicaltrials.gov) - Jun 16, 2017 P1b, N=40, Not yet recruiting,
- |||||||||| Journal: Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays. (Pubmed Central) - Jun 15, 2017
Mutations in genes implicated in cell-to-cell interactions and remodeling of the extracellular matrix and genomic aberrations involving genes coding for the Mediator complex subunits were identified in uterine leiomyomas. Additionally, we discovered that ∼4.6% of leiomyosarcomas harbored MED12 exon 2 mutations, but the relevance of this association with molecular pathogenesis of leiomyosarcoma remains unknown.
- |||||||||| Journal: Integrated Molecular Characterization of Uterine Carcinosarcoma. (Pubmed Central) - Jun 15, 2017
UCSs shared proteomic features with gynecologic carcinomas and sarcomas with intermediate EMT features. Multiple somatic mutations and copy-number alterations in genes that are therapeutic targets were identified.
- |||||||||| Istodax (romidepsin) / Astellas, BMS
Trial completion, Trial initiation date, Trial primary completion date, Metastases: Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 14, 2017 P2, N=40, Completed, Multiple somatic mutations and copy-number alterations in genes that are therapeutic targets were identified. Active, not recruiting --> Completed | Initiation date: Jan 2004 --> Jan 2005 | Trial primary completion date: Jul 2013 --> Oct 2008
- |||||||||| Trial completion, IO biomarker: Predictive Study of Radiation Induced Sarcoma (clinicaltrials.gov) - Jun 12, 2017
P=N/A, N=360, Completed, Initiation date: Apr 2017 --> Aug 2017 | Trial primary completion date: Apr 2019 --> Aug 2019 Enrolling by invitation --> Completed
|